MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Sangamo Therapeutics Inc

Затворен

СекторЗдравеопазване

0.64 12.28

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.55

Максимум

0.65

Ключови измерители

By Trading Economics

Приходи

-34M

-23M

Продажби

-42M

7.6M

EPS

-0.11

Марж на печалбата

-309.84

Служители

183

EBITDA

-34M

-24M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+669.23% upside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-25M

186M

Предишно отваряне

-11.64

Предишно затваряне

0.64

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Sangamo Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.12.2024 г., 11:35 ч. UTC

Значими двигатели на пазара

Sangamo Shares Rally Premarket on License Deal With Astellas

Сравнение с други в отрасъла

Ценова промяна

Sangamo Therapeutics Inc Прогноза

Ценова цел

By TipRanks

669.23% нагоре

12-месечна прогноза

Среден 5 USD  669.23%

Висок 10 USD

Нисък 2 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Sangamo Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

5

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

0.5463 / 0.8561Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.